Core Viewpoint - The company has developed a comprehensive action plan for 2025 aimed at enhancing quality, efficiency, and returns, focusing on its core business of soybean protein and responding to regulatory initiatives to improve the quality of listed companies [1] Group 1: Business Strategy - The company aims to solidify its foundation for high-quality development by focusing on its core business of soybean protein, enhancing operational quality, and optimizing cost control [1][2] - The company is implementing a full-system collaboration model from raw material procurement to sales, ensuring coordinated operations across the supply chain [2] - The company plans to continue enhancing its professional advantages in the soybean protein sector and expand into the plant protein market through technological innovation and product upgrades [2][3] Group 2: Innovation and R&D - The company is committed to an innovation-driven development strategy, focusing on technological advancements and sustainable practices to enhance production efficiency [3][4] - The company has made breakthroughs in key technologies related to soybean protein and is actively collaborating with academic institutions to advance research and development [4] - A systematic intellectual property management system has been established to create technological barriers and enhance overall innovation capabilities [4] Group 3: Investor Relations - The company emphasizes the importance of investor relations management, ensuring timely and accurate information disclosure to protect investor rights [5][6] - Various communication channels have been established to facilitate interaction with investors, including investor meetings and dedicated consultation lines [5][6] - The company has organized investor performance briefings to discuss operational results and financial conditions, maintaining a high response rate to investor inquiries [5][6] Group 4: Corporate Governance - The company is enhancing its internal management controls and decision-making processes to protect the rights of minority shareholders [6][9] - A streamlined and efficient corporate governance structure has been established, ensuring compliance with relevant laws and regulations [6][9] - The company is focused on improving the capabilities of key personnel and enhancing compliance awareness through ongoing training [9] Group 5: Shareholder Returns - The company has a consistent cash dividend policy, having distributed a total of 181.005 million yuan in cash dividends since its listing, representing 41.70% of the total raised funds [7][8] - For the 2024 fiscal year, the company plans to distribute a cash dividend of 0.10 yuan per share, totaling 16.455 million yuan, which is 15.08% of the net profit attributable to shareholders [7][8] - The company aims to maintain a sustainable cash dividend mechanism while balancing operational needs and shareholder returns [8]
山东嘉华生物科技股份有限公司关于2025年度“提质增效重回报”行动方案的公告